Novavax vaccine shows 43% efficacy against South African variant, study finds

Novavax Inc's COVID-19 vaccine had efficacy of 43% against infections caused by the South African variant in a group that included people with and without HIV, and 51% in people who were HIV negative, according to a new analysis published on Wednesday.